Fda grants soligenix "fast track" designation for dusquetide in the treatment of oral lesions of behÇet's disease

Princeton, n.j. , jan. 8, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its sgx945 (dusquetide) development program for the treatment of oral lesions of behÇet's disease has received "fast track" designation from the u.s. food and drug administration (fda).
SNGX Ratings Summary
SNGX Quant Ranking